Genome-based bacterial vaccines: Current state and future outlook

BioDrugs

Volumn 27, Issue 5, 2013, Pages 419-430

  Schubert Unkmeir, Alexandra ^a   Christodoulides, Myron ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; MENINGOCOCCUS VACCINE; PROTEOME;

ALGORITHM; ARTICLE; BACTERIAL GENOME; BIOINFORMATICS; EUKARYOTE; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; GENOME, BACTERIAL; HUMANS;

EID: 84885156419     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0034-5     Document Type: Article

References (119)

1. Hammarsten JF, Tattersall W, Hammarsten JE. Who discovered smallpox vaccination? Edward Jenner or Benjamin Jesty? Trans Am Clin Climatol Assoc. 1979;90:44-55.
2. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent. 2005;18(1):21-5.
3. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9(12):889-93.
4. Telford JL. Bacterial genome variability and its impact on vaccine design. Cell Host Microbe. 2008;3(6):408-16.
5. Lipsitch M, O'Hagan JJ. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface. 2007;4(16):787-802.
6. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269(5223):496-512.
7. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816-20.
8. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445-50.
9. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19(17-19):2688-91.
10. Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012;3:194.
11. Van Regenmortel MH. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine. 2011;29(45):7875.
12. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 2006;24:739-69.
13. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol. 2010;22(3):358-66.
14. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246-51.
15. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2010;84(2):1005-13.
16. Adu-Bobie J, Capecchi B, Serruto D, Rappuoli R, Pizza M. Two years into reverse vaccinology. Vaccine. 2003;21(7-8):605-10.
17. Johnson DA. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem. 2008;8(2):64-79.
18. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3-14.
19. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51-63.
20. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402-7.
21. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355-7.
22. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511-20.
23. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195-207 (discussion 8-10).
24. Rodriguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem Inst Oswaldo Cruz. 1999;94(4):433-40.
25. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340(8827):1074-8.
26. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005;23(17-18):2191-6.
27. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol. 2007;166(7):817-23.
28. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287(5459):1809-15.
29. Palumbo E, Fiaschi L, Brunelli B, Marchi S, Savino S, Pizza M. Antigen identification starting from the genome: a "Reverse Vaccinology" approach applied to MenB. Methods Mol Biol. 2012;799:361-403.
30. Vermont C, van den Dobbelsteen G. Neisseria meningitidis serogroup B: laboratory correlates of protection. FEMS Immunol Med Microbiol. 2002;34(2):89-96.
31. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A. 2010;107(8):3770-5.
32. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177(1):501-10.
33. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176(12):7566-75.
34. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol. 2005;55(3):687-98.
35. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445-54.
36. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834-9.
37. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87-97.
38. Panatto D, Amicizia D, Lai PL, Gasparini R. Neisseria meningitidis B vaccines. Expert Rev Vaccines. 2011;10(9):1337-51.
39. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71-9.
40. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J. 2009;122(1291):48-59.
41. Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8(2):174-83.
42. Wetzler LM. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann N Y Acad Sci. 1994;730:367-70.
43. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011;11(7):969-85.
44. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617-24.
45. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573-82.
46. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127-37.
47. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825-35.
48. Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609-17.
49. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013. doi: 10.1016/S1473-3099(13)70006-9.
50. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490-5.
51. Boccadifuoco G, Brunelli B, Pizza MG, Giuliani MM. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. J Prev Med Hyg. 2012;53(2):56-60.
52. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088-100.
53. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364-71.
54. Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect. 2011;17(9):1294-303.
55. Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, et al. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin Microbiol Infect Dis. 2012;31(9):2097-104.
56. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child. 2003;88(5):375-8.
57. Tettelin H, Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward NL, et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A. 2005;102(39):13950-5.
58. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science. 2005;309(5731):148-50.
59. Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, Rosini R, et al. Genome analysis reveals pili in Group B Streptococcus. Science. 2005;309(5731):105.
60. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G. Pili in gram-positive pathogens. Nat Rev Microbiol. 2006;4(7):509-19.
61. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902.
62. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122-40.
63. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100-21.
64. Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72-7.
65. Weckx LY, Thompson A, Berezin EN, de Faria SM, da Cunha CA, Pride M, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012;30(52):7566-72.
66. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-8.
67. Icardi G, Sticchi L, Bagnasco A, Iudici R, Durando P. Pneumococcal vaccination in adults: rationale, state of the art and perspectives. J Prev Med Hyg. 2012;53(2):78-84.
68. Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011;23(3):407-13.
69. Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine. 2007;25(16):2963-73.
70. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244-56.
71. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun. 2001;69(3):1593-8.
72. Gianfaldoni C, Censini S, Hilleringmann M, Moschioni M, Facciotti C, Pansegrau W, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun. 2007;75(2):1059-62.
73. Harfouche C, Filippini S, Gianfaldoni C, Ruggiero P, Moschioni M, Maccari S, et al. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun. 2012;80(1):451-60.
74. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev. 1995;8(4):451-61.
75. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun. 2002;70(1):368-79.
76. Thorpe C, Edwards L, Snelgrove R, Finco O, Rae A, Grandi G, et al. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine. 2007;25(12):2252-60.
77. Manque PA, Tenjo F, Woehlbier U, Lara AM, Serrano MG, Xu P, et al. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol. 2011;18(11):1796-802.
78. Gan W, Zhao G, Xu H, Wu W, Du W, Huang J, et al. Reverse vaccinology approach identify an Echinococcus granulosus tegumental membrane protein enolase as vaccine candidate. Parasitol Res. 2010;106(4):873-82.
79. Schroeder J, Aebischer T. Vaccines for leishmaniasis: from proteome to vaccine candidates. Hum Vaccin. 2011;7(Suppl):10-5.
80. John L, John GJ, Kholia T. A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp. Appl Biochem Biotechnol. 2012;167(5):1340-50.
81. Zhao BP, Chen L, Zhang YL, Yang JM, Jia K, Sui CY, et al. In silico prediction of binding of promiscuous peptides to multiple MHC class-II molecules identifies the Th1 cell epitopes from secreted and transmembrane proteins of Schistosoma japonicum in BALB/c mice. Microbes Infect. 2011;13(7):709-19.
82. Chaudhuri R, Ahmed S, Ansari FA, Singh HV, Ramachandran S. MalVac: database of malarial vaccine candidates. Malar J. 2008;7:184.
83. Snelling WJ, Xiao L, Ortega-Pierres G, Lowery CJ, Moore JE, Rao JR, et al. Cryptosporidiosis in developing countries. J Infect Dev Ctries. 2007;1(3):242-56.
84. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis. 2012;25(5):555-63.
85. Xu P, Widmer G, Wang Y, Ozaki LS, Alves JM, Serrano MG, et al. The genome of Cryptosporidium hominis. Nature. 2004;431(7012):1107-12.
86. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science. 2004;304(5669):441-5.
87. Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16.
88. Olson PD, Zarowiecki M, Kiss F, Brehm K. Cestode genomics - progress and prospects for advancing basic and applied aspects of flatworm biology. Parasite Immunol. 2012;34(2-3):130-50.
89. Tsai IJ, Zarowiecki M, Holroyd N, Garciarrubio A, Sanchez-Flores A, Brooks KL, et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature. 2013. doi: 10.1038/nature12031.
90. Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine. 2007;25(5):856-66.
91. Maritz-Olivier C, van Zyl W, Stutzer C. A systematic, functional genomics, and reverse vaccinology approach to the identification of vaccine candidates in the cattle tick, Rhipicephalus microplus. Ticks Tick Borne Dis. 2012;3(3):179-87.
92. Stephens DS. Prevention of serogroup B meningococcal disease. Lancet. 2012;379(9816):592-4.
93. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E, et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med. 2011;3(91):91ra62.
94. Nuccitelli A, Cozzi R, Gourlay LJ, Donnarumma D, Necchi F, Norais N, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A. 2011;108(25):10278-83.
95. Vipond C, Suker J, Jones C, Tang C, Feavers IM, Wheeler JX. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics. 2006;6(11):3400-13.
96. Mendum TA, Newcombe J, McNeilly CL, McFadden J. Towards the immunoproteome of Neisseria meningitidis. PLoS One. 2009;4(6):e5940.
97. Williams JN, Skipp PJ, O'Connor CD, Christodoulides M, Heckels JE. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun. 2009;77(11):5080-9.
98. Hedman AK, Li MS, Langford PR, Kroll JS. Transcriptional profiling of serogroup B Neisseria meningitidis growing in human blood: an approach to vaccine antigen discovery. PLoS One. 2012;7(6):e39718.
99. Echenique-Rivera H, Muzzi A, Del Tordello E, Seib KL, Francois P, Rappuoli R, et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog. 2011;7(5):e1002027.
100. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Modelling the cost-effectiveness of new meningococcal vaccines in England. International pathogenic neisseria conference, Banff (2010).
101. Goure J, Findlay WA, Deslandes V, Bouevitch A, Foote SJ, MacInnes JI, et al. Microarray-based comparative genomic profiling of reference strains and selected Canadian field isolates of Actinobacillus pleuropneumoniae. BMC Genomics. 2009;10:88.
102. Palmer GH, Brown WC, Noh SM, Brayton KA. Genome-wide screening and identification of antigens for rickettsial vaccine development. FEMS Immunol Med Microbiol. 2012;64(1):115-9.
103. Song Y, La T, Phillips ND, Bellgard MI, Hampson DJ. A reverse vaccinology approach to swine dysentery vaccine development. Vet Microbiol. 2009;137(1-2):111-9.
104. He Y. Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. Front Cell Infect Microbiol. 2012;2:2.
105. Zhang M, Wu H, Li X, Yang M, Chen T, Wang Q, et al. Edwardsiella tarda flagellar protein FlgD: a protective immunogen against edwardsiellosis. Vaccine. 2012;30(26):3849-56.
106. Liebenberg J, Pretorius A, Faber FE, Collins NE, Allsopp BA, van Kleef M. Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy. Vet Immunol Immunopathol. 2012;145(1-2):340-9.
107. Sebatjane SI, Pretorius A, Liebenberg J, Steyn H, Van Kleef M. In vitro and in vivo evaluation of five low molecular weight proteins of Ehrlichia ruminantium as potential vaccine components. Vet Immunol Immunopathol. 2010;137(3-4):217-25.
108. Nesta B, Spraggon G, Alteri C, Moriel DG, Rosini R, Veggi D, et al. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio. 2012;3(2). doi: 10.1128/mBio.00010-12.
109. Moriel DG, Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B, et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A. 2010;107(20):9072-7.
110. Hong M, Ahn J, Yoo S, Hong J, Lee E, Yoon I, et al. Identification of novel immunogenic proteins in pathogenic Haemophilus parasuis based on genome sequence analysis. Vet Microbiol. 2011;148(1):89-92.
111. Umamaheswari A, Pradhan D, Hemanthkumar M. Computer aided subunit vaccine design against pathogenic Leptospira serovars. Interdiscip Sci. 2012;4(1):38-45.
112. Yang HL, Zhu YZ, Qin JH, He P, Jiang XC, Zhao GP, et al. In silico and microarray-based genomic approaches to identifying potential vaccine candidates against Leptospira interrogans. BMC Genomics. 2006;7:293.
113. Hatfaludi T, Al-Hasani K, Gong L, Boyce JD, Ford M, Wilkie IW, et al. Screening of 71 P. multocida proteins for protective efficacy in a fowl cholera infection model and characterization of the protective antigen PlpE. PLoS One. 2012;7(7):e39973.
114. Ross BC, Czajkowski L, Hocking D, Margetts M, Webb E, Rothel L, et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine. 2001;19(30):4135-42.
115. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, Manetti AG, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A. 2005;102(43):15641-6.
116. Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol. 2006;24(2):191-7.
117. Ge X, Kitten T, Munro CL, Conrad DH, Xu P. Pooled protein immunization for identification of cell surface antigens in Streptococcus sanguinis. PLoS One. 2010;5(7):e11666.
118. Liu L, Cheng G, Wang C, Pan X, Cong Y, Pan Q, et al. Identification and experimental verification of protective antigens against Streptococcus suis serotype 2 based on genome sequence analysis. Curr Microbiol. 2009;58(1):11-7.
119. Graham SP, Honda Y, Pelle R, Mwangi DM, Glew EJ, de Villiers EP, et al. A novel strategy for the identification of antigens that are recognised by bovine MHC class I restricted cytotoxic T cells in a protozoan infection using reverse vaccinology. Immunome Res. 2007;3:2.